Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 55Endometrial Neoplasms 7Ovarian Neoplasms 5Neoplasm Metastasis 5Polycystic Ovary Syndrome 4Neoplasms 4Advanced Breast Cancer 4Triple Negative Breast Neoplasms 3Prostatic Neoplasms 3Carcinoma, Intraductal, Noninfiltrating 3Recurrence 2Neoplasms by Site 2Infertility 2HR+/HER2- Breast Cancer 2Estrogen Receptor-positive Breast Cancer 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms, Male 2Breast Diseases 2Uterine Cervical Neoplasms 1Unilateral Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sexual Dysfunctions, Psychological 1Pathologic Complete Response 1Pancreatic Neoplasms 1Low-Grade Serous Ovarian Cancer 1Low Grade Serous Ovarian Carcinoma 1Low Grade Serous Ovarian Cancer 1Locoregional Recurrence 1Leiomyoma 1

Interventions

trastuzumab biosimilar HLX02 1exemestane 1X-Rays 1Trastuzumab 1Taxes 1TVB-2640 1Specimen Handling 1Paclitaxel 1PF-05280014 1Ontruzant 1Ogivri 1Magnetic Resonance Spectroscopy 1Letrozole 1Fulvestrant 1Disulfides 1CT-P6 1Biopsy 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Breast Carcinoma × Letrozole × 90 days × Clear all
NCT03179904 2026-05-05

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

Mayo Clinic

Phase 2 Active not recruiting
17 enrolled 10 charts
Breast

Advanced Breast Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡